Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune Thrombocytopenia
Table 1
Patient’s clinical and laboratory characteristics.
Clinical and laboratory characteristics
Rapa group
CsA group
Patients number
43
45
Females/males
29/14
32/13
0.713
Mean age, years
34 (13–65)
36 (14–58)
0.456
Mean duration, years
3 (2–6)
3 (2–6)
0.420
Mean bleeding grade (WHO Bleeding Scale)
1 (0–2)
1 (0–2)
0.377
Mean baseline platelet count, ×109/L
22.25 (11–32)
21.82 (11–35)
0.747
Mean MEG count in bone marrow slide
105 (34–231)
100 (34–241)
0.710
Platetle antibody, yes/no
28/15
28/17
0.781
Mean days since the last treatment
63 (10–365)
57 (10–365)
0.664
Mean numbers of previous treatments
3 (2–6)
3 (2–5)
0.106
Previous treatments number
43
45
Steroids
43
45
Intravenous immune globulin
17
21
Danazol
16
19
Azathioprine
10
14
Vincristine
2
1
Rituximab
1
0
The previous treatments included Steroids, intravenous immune globulin, Rituximab, Danazol, Azathioprine, and Vincristine; the determination of platelet antibody included glycoproteins IIb/IIIa/Ib/IX. MEG: megakaryocyte; Rapa: rapamycin; CsA: cyclosporine A.
